AUTHOR=Cheng Sha , Li Huan , Luo Ju , Chi Jingshu , Zhao Wenfang , Lin Jiahui , Xu Canxia 

TITLE=Egg yolk antibody combined with bismuth-based quadruple therapy in Helicobacter pylori infection rescue treatment: a single-center, randomized, controlled study

JOURNAL=Frontiers in Microbiology

VOLUME=14

YEAR=2023

URL=https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2023.1150129

DOI=10.3389/fmicb.2023.1150129

ISSN=1664-302X

ABSTRACT=<sec><title>Background</title><p>The increasing antibiotic resistance is the main issue causing <italic>Helicobacter pylori</italic> (<italic>H. pylori</italic>) eradication failure. As a nutritional supplement, Egg Yolk Antibody (Ig Y) provides a new approach for <italic>H. pylori</italic> infection rescue therapy.</p></sec><sec><title>Methods</title><p>In this randomized, controlled study, 100 <italic>H. pylori</italic>-positive patients with previous <italic>H. pylori</italic> eradication treatment were included. All individuals received standard bismuth-containing quadruple therapy twice daily (5 mg ilaprazole, 100 mg doxycycline, 500 mg clarithromycin or 1 g amoxicillin or 100 mg furazolidone, and 220 mg colloidal bismuth tartrate) for 14 days and were randomized to receive either twice daily 7 g Ig Y-<italic>H. pylori</italic> treatment (study group) or not (control group). 4 weeks after the end of treatment, urea breath tests were used to assess the <italic>H. pylori</italic> eradication rate. All participants scored by the Global Overall Symptom scale (GOS) and recorded adverse events during the trial.</p></sec><sec><title>Results</title><p>The <italic>H. pylori</italic> eradication rates were 84.0% (95% CI 73.5–94.5%) vs. 80.0% (95% CI 68.5–91.5%) in the study and control groups at intention-to-treat (ITT) analysis and 85.7% (95% CI 75.6–95.9%) vs. 80.0% (95% CI 68.5–91.5%) at per-protocol (PP) analysis, respectively. The number of over 80% symptom relief after treatment in the two groups was 27 (60%) and 12 (29.2%) (<italic>p</italic> &lt; 0.05), and the incidences of adverse events were 4 (8%) and 6 (12%), respectively.</p></sec><sec><title>Conclusion</title><p>Both groups achieved satisfactory eradication efficiency in <italic>H. pylori</italic> rescue therapy and Ig Y-<italic>H. pylori</italic> effectively alleviates the symptoms with good compliance and fewer adverse effects.</p></sec>